
Did Our Public Health Institutions Learn Anything From COVID? | Scott Gottlieb, MD
Hold These Truths with Dan Crenshaw
00:00
Is It a Revolving Door?
The FDA is trying to approve drugs early enough in the course of these diseases so that you can actually arrest the disease process. There's no theoretical way, at least available right now, therapeutically, to restore that function. The debate recently about the drug um from birogen for ashamers,. i think, ilustrates this point. We promulgated a guidance in 20 18 when i was there, that basically said, for neurodegen diseases like lugaric disease, you're not going to help that person regain their function.
Transcript
Play full episode